Author index

ABE, K. *see* KAMOHARA, H.
ACKERMANN, L.W. & DENNING, G.M. Nuclear factor-κB contributes to interleukin-4- and interferon-dependent polymeric immunoglobulin receptor expression in human intestinal epithelial cells, 75
AHMED, S. *see* OZEGBE, P.
AKAHIRA-AZUMA, M., SZCZEPANIK, M., TSUJI, R.F., CAMPOS, R.A., ITAKURA, A., MOBINI, N., MCNIFF, J., KAWIKOVA, I., LU, B., GERARD, C., POBER, J.S. & ASKENASE, P. W. Early delayed-type hypersensitivity eosinophil infiltrates depend on T helper 2 cytokines and interferon-γ via CXCR3 chemokines, 306
AKIRA, S. *see* GOMES, M.S.
ALLEN, J. *see* URONEN-HANSSON, H.
AMBROSE, H.E. & WAGNER, S.D. α6-Integrin is expressed on germinal centre B cells and modifies growth of a B-cell line, 400
APPELBERG, R. *see* FLÓRIDO, M.
APPELBERG, R. *see* GOMES, M.S.
ASKENASE, P.W. *see* AKAHIRA-AZUMA, M.
ATTANASIO, R. *see* SCINICARIELLO, F.
AYUB, K. & HALLETT, M.B. Ca^{2+} influx shutdown during neutrophil apoptosis: importance and possible mechanism, 8

BÁEZ, R. *see* JIMÉNEZ-MARTÍNEZ, M.C.
BAI, H. *see* QIU, H.
BAOJUN, H. *see* LI, H.
BARABANOVA, Y.A., KANG, H.-K., MYOUNG, J., KANG, B., BISHOP, G.A. & KIM, B.S. Role of the major histocompatibility complex class II transmembrane region in antigen presentation and intracellular trafficking, 165
BARNES, P.J. *see* BERGMANN, M.W.
BARTHLOTT, T. *see* DE JERSEY, J.
BARTHLOTT, T. *see* STOCKINGER, B.
BAXTER, A.G. *see* SMALLWOOD, L.
BELL, E.B. *see* BERESFORD, L.
BERESFORD, L., ORANGE, O., BELL, E.B. & MIYAN, J.A. Nerve fibres are required to evoke a contact sensitivity response in mice, 118
BERGMANN, M.W., STAPLES, K.J., BARNES, P.J. & NEWTON, R. Nuclear factor-κB does not mediate the inhibitory effects of dexamethasone on granulocyte–macrophage colony-stimulating factor expression, 430
BERTINI, R. *see* DI CIOCCIO, V.
BISHOP, G.A. *see* BARABANOVA, Y.A.
BIZZARRI, C. *see* DI CIOCCIO, V.
BOHBOT, A. *see* SIGRIST, S.
BOONS, G.-J. *SEE* NARENDRAN, P.
BORLAND, G. & CUSHLEY, W. Positioning the immune system: unexpected roles for α6-integrins, 381
BOROS, D.L. *see* SINGH, K.P.
BOSSUYT, X. *see* JEURISSEN, A.
BRADNEY, C. *see* PAN, L.
BRANDTZAEG, P. *see* MORTON, H.C.
BREWER, J.M. *see* SMITH, K.M.
BRILL, A. *see* SELA, U.
BROOKE, G.P. *see* GLIDDON, D.R.
BUCHER, P. *see* SIGRIST, S.

CALLARD, R.E. *see* URONEN-HANSSON, H.
CAMPOS, R.A. *see* AKAHIRA-AZUMA, M.
CARAMALHO, Í. *see* VILANOVA, M.
CARMIGNAC, D. *see* DE JERSEY, J.
CAROSELLA, E.D. *see* ROUSSEAU, P.
CATTOZZO, E.M. *see* DI CIOCCIO, V.
CERVELLERA, M.N. *see* DI CIOCCIO, V.
CEUPPENS, J.L. *see* JEURISSEN, A.
CHÁVEZ, R. *see* JIMÉNEZ-MARTÍNEZ, M.C.
CHALLACOMBE, S. *see* WILLIAMS, A.
CHEN, L. *see* QIU, H.
CHO, D. *see* KIM, E.J.
CHUNG, Y., KIM, D.-H., LEE, S.-H. & KANG, C.-Y. Co-administration of CD40 agonistic antibody and antigen fails to overcome the induction of oral tolerance, 19
CHUNSONG, H. *see* LI, H.
CLARK, S.O. *see* WILLIAMS, A.
COHN, M. An alternative to current thinking about positive selection, negative selection and activation of T cells, 375
COLAGRANDE, A. *see* DI CIOCCIO, V.
COLOTTA, F. *see* DI CIOCCIO, V.
CONNOR, T.J. Methylenedioxymethamphetamine (MDMA, 'Ecstasy'): a stressor on the immune system, 357
CORDEIRO, J.V. *see* GOMES, M.S.
COSENTINI, E. *see* RUGGIERO, G.
CUSHLEY, W. *see* BORLAND, G.

DARLOW, J.M., FARRELL, A.M. & STOTT, D.I. Non-functional immunoglobulin G transcripts in a case of hyper-immunoglobulin M syndrome similar to type 4, 212
DAUSSET, J. *see* ROUSSEAU, P.
DAVIES, M.L., HOPKINS, L.J., HALLIDAY, S., HOUSTON, F., HUNTER, N. & MCCONNELL, I. Architecture of secondary lymphoid tissue in sheep experimentally challenged with scrapie, 230
DAYAN, C.M. *see* NARENDRAN, P.
DE JERSEY, J., CARMIGNAC, D., LE TISSIER, P., BARTHLOTT, T., ROBINSON, I. & STOCKINGER, B. Factors affecting the susceptibility of the mouse pituitary gland to CD8 T-cell-mediated autoimmunity, 254
DEMENGEOT, J. *see* VILANOVA, M.
DENNING, G.M. *see* ACKERMANN, L.W.
DI CIOCCIO, V., STRIPPOLI, R., BIZZARRI, C., TROIANI, G., CERVELLERA, M.N., GLOAGUEN, I., COLAGRANDE, A., CATTOZZO, E.M., PAGLIEI, S., SANTONI, A., COLOTTA, F., MAINIERO, F. & BERTINI, R. Key role of proline-rich tyrosine kinase 2 in interleukin-8 (CXCL8/IL-8)-mediated human neutrophil chemotaxis, 407
DIESEL, C. *see* GUTZMER, R.
DISSEN, E. *see* MORTON, H.C.
DOCKRELL, H.M. *see* HUSSAIN, R.
DOJKI, M. *see* HUSSAIN, R.

ELSEGOOD, K. *see* NARENDRAN, P.
ENGLEMAN, C.N. *see* SCINICARIELLO, F.
ESPOSITO, G. *see* SIGRIST, S.

FAHEY, J.V. *see* WIRA, C.R.
FALERO-DIAZ, G. *see* WILLIAMS, A.
FAN, Y. *see* QIU, H.
FARRELL, A.M. *see* DARLOW, J.M.
FERNIE-KING, B.A., SEILLY, D.J. & LACHMANN, P.J. The interaction of streptococcal inhibitor of complement (SIC) and its proteolytic fragments with the human beta defensins, 444
FERREIRA, P. *see* VILANOVA, M.
FLÓRIDO, M. *see* GOMES, M.S.
FLÓRIDO, M., GONÇALVES, A.S., GOMES, M.S. & APPELBERG, R. CD40 is required for the optimal induction of protective immunity to *Mycobacterium avium*, 323
FLOROS, J. *see* MACNEILL, C.
FOEY, A.D. *see* OZEGBE, P.

GALLIGAN, C. *see* KAMOHARA, H.
GAMA, M. *see* VILANOVA, M.
GANOR, S. *see* SELA, U.
GARSIDE, P. *see* SMITH, K.M.
GERARD, C. *see* AKAHIRA-AZUMA, M.
GERARD, H.C. *see* SINGH, K.P.
GLIDDON, D.R., HOPE, J.C., BROOKE, G.P. & HOWARD, C.J. DEC-205 expression on migrating dendritic cells in afferent lymph, 262
GLOAGUEN, I. *see* DI CIOCCIO, V.
GOMES, M.S. *see* FLÓRIDO, M.
GOMES, M.S., FLÓRIDO, M., CORDEIRO, J.V., TEIXEIRA, C.M., TAKEUCHI, O., AKIRA, S. & APPELBERG, R. Limited role of the Toll-like receptor-2 in resistance to *Mycobacterium avium*, 179
GONÇALVES, A.S. *see* FLÓRIDO, M.
GOODIER, M.R. & LONDEI, M. CD28 is not directly involved in the response of human $CD3^-CD56^+$ natural killer cells to lipopolysaccharide: a role for T cells, 384
GOROCICA, P. *see* JIMÉNEZ-MARTÍNEZ, M.C.
GUOBIN, C. *see* LI, H.
GUTZMER, R., LISEWSKI, M., ZWIRNER, J., MOMMERT, S., DIESEL, C., WITTMANN, M., KAPP, A. & WERFEL, T. Human monocyte-derived dendritic cells are chemoattracted to C3a after up-regulation of the C3a receptor with interferons, 435

HALLETT, M.B. *see* AYUB, K.
HALLIDAY, S. *see* DAVIES, M.L.
HAN, X. *see* QIU, H.
HASHIMOTO, S.-I. *see* KAMOHARA, H.
HAYASHI, Y. *see* NAGATA, Y.
HECHT, I. *see* SELA, U.
HERSHKOVIZ, R. *see* SELA, U.
HIGASHIYAMA, H. *see* NAGATA, Y.
HOPE, J.C. *see* GLIDDON, D.R.
HOPE, J.C. *see* WERLING, D.
HOPKINS, L.J. *see* DAVIES, M.L.
HOUSTON, F. *see* DAVIES, M.L.
HOWARD, C.J. *see* GLIDDON, D.R.
HOWARD, C.J. *see* WERLING, D.

HUDSON, A.P. *see* SINGH, K.P.
HUNTER, N. *see* DAVIES, M.L.
HUSSAIN, R., SHAHID, F., ZAFAR, S., DOJKI, M. & DOCKRELL, H.M. Immune profiling of leprosy and tuberculosis patients to 15-mer peptides of *Mycobacterium leprae* and *M. tuberculosis* GroES in a BCG vaccinated area: implications for development of vaccine and diagnostic reagents, 462
HWANG, H.-Y. *see* IMAI, M.

IMAI, M., HWANG, H.-Y., NORRIS, J.S. & TOMLINSON, S. The effect of dexamethasone on human mucin 1 expression and antibody-dependent complement sensitivity in a prostate cancer cell line *in vitro* and *in vivo*, 291
INOUE, H. *see* NAGATA, Y.
ITAKURA, A. *see* AKAHIRA-AZUMA, M.
IVANYI, J. *see* WILLIAMS, A.

JAYASHANKAR, L. *see* SCINICARIELLO, F.
JEURISSEN, A., CEUPPENS, J.L. & BOSSUYT, X. T lymphocyte dependence of the antibody response to 'T lymphocyte independent type 2' antigens, 1
JIMÉNEZ-MARTÍNEZ, M.C., LINARES, M., BAEZ, R., MONTAÑO, L.F., MARTÍNEZ-CAIRO, S., GOROCICA, P., CHÁVEZ, R., ZENTENO, E. & LASCURAIN, R. Intracellular expression of interleukin-4 and interferon-γ by a *Mycobacterium tuberculosis* antigen-stimulated $CD4^+$ $CD57^+$ T-cell subpopulation with memory phenotype in tuberculosis patients, 100
JINQUAN, T. *see* LI, H.
JUNGI, T.W. *see* WERLING, D.
JUNYAN, L. *see* LI, H.

KAMOHARA, H., MATSUYAMA, W., SHIMOZATO, O., ABE, K., GALLIGAN, C., HASHIMOTO, S.-I., MATSUSHIMA, K. & YOSHIMURA, T. Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptor expression in human neutrophils, 186
KANG, B. *see* BARABANOVA, Y.A.
KANG, C.-Y. *see* CHUNG, Y.
KANG, H.-K. *see* BARABANOVA, Y.A.
KAPP, A. *see* GUTZMER, R.
KAPP, J.A., KAPP, L.M., MCKENNA, K.C. & LAKE, J.P. γδ T-cell clones from intestinal intraepithelial lymphocytes inhibit development of CTL responses *ex vivo*, 155
KAPP, L.M. *see* KAPP, J.A.
KASSIOTIS, G. *see* STOCKINGER, B.
KAWANO, H. *see* YASUDA, K.
KAWIKOVA, I. *see* AKAHIRA-AZUMA, M.
KEMENY, D.M. *see* SALAGIANNI, M.
KESSLER, L. *see* SIGRIST, S.
KIM, B.S. *see* BARABANOVA, Y.A.
KIM, D.-H. *see* CHUNG, Y.
KIM, E.J., CHO, D. & KIM, T.S. Efficient induction of T helper type 1-mediated immune responses in antigen-primed mice by anti-CD3 single-chain Fv/interleukin-18 fusion DNA, 27
KIM, T.S. *see* KIM, E.J.
KIZU, Y. *see* NAGATA, Y.
KLEIN, N. *see* URONEN-HANSSON, H.
KRAWCZYK, M. *see* ROUSSEAU, P.

LACHMANN, P.J. *see* FERNIE-KING, B.A.
LAKE, J.P. *see* KAPP, J.A.
LAMARTINE, R. *see* SIGRIST, S.
LASCURAIN, R. *see* JIMÉNEZ-MARTÍNEZ, M.C.
LE TISSIER, P. *see* DE JERSEY, J.
LEE, S.-H. *see* CHUNG, Y.
LEECH, N.J. *see* NARENDRAN, P.
LESLIE, R.G.Q. & NIELSEN, C. H. The classical and alternative pathways of complement activation play distinct roles in spontaneous C3 fragment deposition and membrane attack complex (MAC) formation on human B lymphocytes, 86
LI, H., CHUNSONG, H., GUOBIN, C., QIUPING, Z., QUN, L., XIAOLIAN, Z., BAOJUN, H., LINJIE, Z., JUNYAN, L., MINGSHEN, J. & JINQUAN, T. Highly up-regulated CXCR3 expression on eosinophils in mice infected with *Schistosoma japonicum*, 107
LIDER, O. *see* SELA, U.
LIN, Z. *see* MACNEILL, C.
LINARES, M. *see* JIMÉNEZ-MARTÍNEZ, M.C.
LINJIE, Z. *see* LI, H.
LISEWSKI, M. *see* GUTZMER, R.
LONDEI, M. *see* GOODIER, M.R.
LU, B. *see* AKAHIRA-AZUMA, M.

MACNEILL, C., UMSTEAD, T.M., PHELPS, D.S., LIN, Z., FLOROS, J., SHEARER, D.A. & WEISZ, J. Surfactant protein A, an innate immune factor, is expressed in the vaginal mucosa and is present in vaginal lavage fluid, 91
MACINDOE, W.M. *see* NARENDRAN, P.
MADRID-MARINA, V. *see* PERALTA-ZARAGOZA, O.
MADUREIRA, P. *see* VILANOVA, M.
MAEDA, S.M. *see* SUNDERKÖTTER, C.H.
MAINIERO, F. *see* DI CIOCCIO, V.
MANDES, K. *see* SIGRIST, S.
MARIANO, M. *see* SUNDERKÖTTER, C.H.
MARQUES, A. *see* VILANOVA, M.
MARSH, P.D. *see* WILLIAMS, A.
MARTÍNEZ-CAIRO, S. *see* JIMÉNEZ-MARTÍNEZ, M.C.
MASTERNAK, K. *see* ROUSSEAU, P.
MATARESE, G. *see* RUGGIERO, G.
MATSUSHIMA, K. *see* KAMOHARA, H.
MATSUYAMA, W. *see* KAMOHARA, H.
MCCLURE, H.M. *see* SCINICARIELLO, F.
MCCONNELL, I. *see* DAVIES, M.L.
MCKENNA, K.C. *see* KAPP, J.A.
MCNIFF, J. *see* AKAHIRA-AZUMA, M.
MINGSHEN, J. *see* LI, H.
MIRELMAN, D. *see* SELA, U.
MIRON, T. *see* SELA, U.
MISHIMA, K. *see* NAGATA, Y.
MIYAN, J.A. *see* BERESFORD, L.
MIZUNO, F. *see* NAGATA, Y.
MOBINI, N. *see* AKAHIRA-AZUMA, M.
MOMMERT, S. *see* GUTZMER, R.
MONTAÑO, L.F. *see* JIMÉNEZ-MARTÍNEZ, M.C.
MOREAU, P. *see* ROUSSEAU, P.
MORTON, H.C., PLEASS, R.J., STORSET, A.K., DISSEN, E., WILLIAMS, J.L., BRANDTZAEG, P. & WOOF, J.M. Cloning and characterization of an immunoglobulin A Fc receptor from cattle, 204
MOWAT, A.M. *see* SMITH, K.M.
MYOUNG, J. *see* BARABANOVA, Y.A.

NAGAOKA, I. *see* NIYONSABA, F.
NAGATA, Y., INOUE, H., YAMADA, K., HIGASHIYAMA, H., MISHIMA, K., KIZU, Y., TAKEDA, I., MIZUNO, F., HAYASHI, Y. & SAITO, I. Activation of Epstein–Barr virus by saliva from Sjogren's syndrome patients, 223
NARENDRAN, P., ELSEGOOD, K., LEECH, N.J., MACINDOE, W.M., BOONS, G.-J. & DAYAN, C.M. Dendritic cell-based assays, but not mannosylation of antigen, improves detection of T-cell responses to proinsulin in type 1 diabetes, 422
NAYLOR, I. *see* WILLIAMS, A.
NEWTON, R. *see* BERGMANN, M.W.
NIELSEN, C.H. *see* LESLIE, R.G.Q.
NISHIKAWA, M. *see* YASUDA, K.
NIX, V. *see* SUNDERKÖTTER, C.H.
NIYONSABA, F., OGAWA, H. & NAGAOKA, I. Human β-defensin-2 functions as a chemotactic agent for tumour necrosis factor-α-treated human neutrophils, 273
NORRIS, J.S. *see* IMAI, M.

OBERHOLZER, J. *see* SIGRIST, S.
OGAWA, H. *see* NIYONSABA, F.
OGAWA, Y. *see* YASUDA, K.
ORANGE, O. *see* BERESFORD, L.
OSMAN, M. *see* URONEN-HANSSON, H.
OZEGBE, P., FOEY, A.D., AHMED, S. & WILLIAMS, R.O. Impact of cAMP on the T-cell response to type II collagen, 35

PAGLIEI, S. *see* DI CIOCCIO, V.
PAN, L., BRADNEY, C., ZHENG, B. & ZHUANG, Y. Altered T-dependent antigen responses and development of autoimmune symptoms in mice lacking E2A in T lymphocytes, 147
PERALTA-ZARAGOZA, O., RECILLAS-TARGA, F. & MADRID-MARINA, V. Terminal deoxynucleotidyl transferase is down-regulated by AP-1-like regulatory elements in human lymphoid cells, 195
PERNA, F. *see* RUGGIERO, G.
PHELPS, D.S. *see* MACNEILL, C.
PINGET, M. *see* SIGRIST, S.
PLEASS, R.J. *see* MORTON, H.C.
POBER, J.S. *see* AKAHIRA-AZUMA, M.
PUGLIESE, A. Central and peripheral autoantigen presentation in immune tolerance, 138

QIU, H., YANG, J., BAI, H., FAN, Y., WANG, S., HAN, X., CHEN, L. & YANG, X. Less inhibition of interferon-γ to organism growth in host cells may contribute to the high susceptibility of C3H mice to *Chlamydia trachomatis* lung infection, 453
QIUPING, Z. *see* LI, H.
QUN, L. *see* LI, H.

RABINKOV, A. *see* SELA, U.
RECILLAS-TARGA, F. *see* PERALTA-ZARAGOZA, O.
REITH, W. *see* ROUSSEAU, P.
RELJIC, R. *see* WILLIAMS, A.
RIBEIRO, A. *see* VILANOVA, M.
ROBINSON, I. *see* DE JERSEY, J.
RON, Y. *see* SMITH, K.M.
ROTH, J. *see* SUNDERKÖTTER, C.H.
ROTONDO, D. *see* WALKER, W.

ROUSSEAU, P., MASTERNAK, K., KRAWCZYK, M., REITH, W., DAUSSET, J., CAROSELLA, E.D. & MOREAU, P. *In vivo*, RFX5 binds differently to the human leucocyte antigen-E, -F, and -G gene promoters and participates in HLA class I protein expression in a cell type-dependent manner, 53
RUDD, C.E. *see* WILKINSON, B.
RUGGIERO, G., COSENTINI, E., ZANZI, D., SANNA, V., TERRAZZANO, G., MATARESE, G., SANDUZZI, A., PERNA, F. & ZAPPACOSTA, S. Allelic distribution of human leucocyte antigen in historical and recently diagnosed tuberculosis patients in Southern Italy, 318

SAITO, I. *see* NAGATA, Y.
SALAGIANNI, M. & KEMENY, D.M. Anti-CD3 sFv/IL-18 fusion DNA for allergy therapy, 16
SANDUZZI, A. *see* RUGGIERO, G.
SANNA, V. *see* RUGGIERO, G.
SANTONI, A. *see* DI CIOCCIO, V.
SCINICARIELLO, F., ENGLEMAN, C.N., JAYASHANKAR, L., MCCLURE, H.M. & ATTANASIO, R. Rhesus macaque antibody molecules: sequences and heterogeneity of alpha and gamma constant regions, 66
SEILLY, D.J. *see* FERNIE-KING, B.A.
SELA, U., GANOR, S., HECHT, I., BRILL, A., MIRON, T., RABINKOV, A., WILCHEK, M., MIRELMAN, D., LIDER, O. & HERSHKOVIZ, R. Allicin inhibits SDF-1α-induced T cell interactions with fibronectin and endothelial cells by down-regulating cytoskeleton rearrangement, Pyk-2 phosphorylation and VLA-4 expression, 391
SHAHID, F. *see* HUSSAIN, R.
SHEARER, D.A. *see* MACNEILL, C.
SHIMOZATO, O. *see* KAMOHARA, H.
SIGRIST, S., OBERHOLZER, J., BOHBOT, A., ESPOSITO, G., MANDES, K., LAMARTINE, R., TOSO, C., BUCHER, P., PINGET, M. & KESSLER, L. Activation of human macrophages by allogeneic islets preparations: inhibition by AOP-RANTES and heparinoids, 416
SINDRILARU, A. *see* SUNDERKÖTTER, C.H.
SINGH, K.P., GERARD, H.C., HUDSON, A.P. & BOROS, D. L. Expression of matrix metalloproteinases and their inhibitors during the resorption of schistosome egg-induced fibrosis in praziquantel-treated mice, 343
SINGH, M. *see* WILLIAMS, A.
SMALLWOOD, L. & BAXTER, A. G. On lawnmowers and lay-down misères, 252
SMITH, K.M., BREWER, J.M., MOWAT, A.M., RON, Y. & GARSIDE, P. The influence of follicular migration on T-cell differentiation, 248
SORG, C. *see* SUNDERKÖTTER, C.H.
SQUIRES, G. *see* URONEN-HANSSON, H.
STAPLES, K.J. *see* BERGMANN, M.W.
STOCKINGER, B. *see* DE JERSEY, J.
STOCKINGER, B., BARTHLOTT, T. & KASSIOTIS, G. The concept of space and competition in immune regulation, 241
STORSET, A.K. *see* MORTON, H.C.
STOTT, D.I. *see* DARLOW, J.M.
STRIPPOLI, R. *see* DI CIOCCIO, V.
SUNDERKÖTTER, C.H., TOMIMORI-YAMASHITA, J., NIX, V., MAEDA, S.M., SINDRILARU, A., MARIANO, M., SORG, C. & ROTH, J. High expression of myeloid-related proteins 8 and 14 characterizes an inflammatorily active but ineffective response of macrophages during leprosy, 472
SZCZEPANIK, M. *see* AKAHIRA-AZUMA, M.

TAKAKURA, Y. *see* YASUDA, K.
TAKEDA, I. *see* NAGATA, Y.
TAKEUCHI, O. *see* GOMES, M.S.
TEIXEIRA, C.M. *see* GOMES, M.S.
TEIXEIRA, L. *see* VILANOVA, M.
TERRAZZANO, G. *see* RUGGIERO, G.
TOMIMORI-YAMASHITA, J. *see* SUNDERKÖTTER, C.H.
TOMLINSON, S. *see* IMAI, M.
TORRADO, E. *see* VILANOVA, M.
TOSO, C. *see* SIGRIST, S.
TROIANI, G. *see* DI CIOCCIO, V.
TSUJI, R.F. *see* AKAHIRA-AZUMA, M.

UMSTEAD, T.M. *see* MACNEILL, C.
URONEN-HANSSON, H., ALLEN, J., OSMAN, M., SQUIRES, G., KLEIN, N. & CALLARD, R.E. Toll-like receptor 2 (TLR2) and TLR4 are present inside human dendritic cells, associated with microtubules and the Golgi apparatus but are not detectable on the cell surface: integrity of microtubules is required for interleukin-12 production in response to internalized bacteria, 173

VILANOVA, M., TEIXEIRA, L., CARAMALHO, Í., TORRADO, E., MARQUES, A., MADUREIRA, P., RIBEIRO, A., FERREIRA, P., GAMA, M. & DEMENGEOT, J. Protection against systemic candidiasis in mice immunized with secreted aspartic proteinase 2, 334

WAGNER, S.D. *see* AMBROSE, H.E.
WALKER, L.S.K. $CD4^+$ $CD25^+$ Treg: divide and rule?, 129
WALKER, W. & ROTONDO, D. Prostaglandin E_2 is a potent regulator of interleukin-12- and interleukin-18-induced natural killer cell interferon-γ synthesis, 298
WANG, H. *see* WILKINSON, B.
WANG, S. *see* QIU, H.
WEISZ, J. *see* MACNEILL, C.
WERFEL, T. *see* GUTZMER, R.
WERLING, D., HOPE, J.C., HOWARD, C.J. & JUNGI, T.W. Differential production of cytokines, reactive oxygen and nitrogen by bovine macrophages and dendritic cells stimulated with Toll-like receptor agonists, 41
WILCHEK, M. *see* SELA, U.
WILKINSON, B., WANG, H. & RUDD, C.E. Positive and negative adaptors in T-cell signalling, 368
WILLIAMS, A., RELJIC, R., NAYLOR, I., CLARK, S.O., FALERO-DIAZ, G., SINGH, M., CHALLACOMBE, S., MARSH, P.D. & IVANYI, J. Passive protection with immunoglobulin A antibodies against tuberculous early infection of the lungs, 328
WILLIAMS, J.L. *see* MORTON, H.C.
WILLIAMS, R.O. *see* OZEGBE, P.
WIRA, C.R. & FAHEY, J.V. The innate immune system: gatekeeper to the female reproductive tract, 13
WITTMANN, M. *see* GUTZMER, R.
WOOF, J.M. *see* MORTON, H.C.

XIAOLIAN, Z. *see* LI, H.

YAMADA, K. *see* NAGATA, Y.
YAMANE, I. *see* YASUDA, K.
YANG, J. *see* QIU, H.
YANG, X. *see* QIU, H.
YASUDA, K., KAWANO, H., YAMANE, I., OGAWA, Y., YOSHINAGA, T., NISHIKAWA, M. & TAKAKURA, Y. Restricted cytokine production from mouse peritoneal macrophages in culture in spite of extensive uptake of plasmid DNA, 282
YOSHIMURA, T. *see* KAMOHARA, H.
YOSHINAGA, T. *see* YASUDA, K.

ZAFAR, S. *see* HUSSAIN, R.
ZANZI, D. *see* RUGGIERO, G.
ZAPPACOSTA, S. *see* RUGGIERO, G.
ZENTENO, E. *see* JIMÉNEZ-MARTÍNEZ, M.C.
ZHENG, B. *see* PAN, L.
ZHUANG, Y. *see* PAN, L.
ZWIRNER, J. *see* GUTZMER, R.

Subject index

γδT cells:
depletion, 155
TDR-δ chain, 155

Adaptive immunity:
antibody response, 453
cytokine production, 453
DTH, 453
Adhesion molecule, 391
Adjuvants/CpG DNA, 282
Allergy:
cytokines, 306
delayed type sensitivity, 306
hypersensitivity, 306
Th1/Th2 cytokines, 306
Anergy, 129
Anergy/suppression/tolerance, 248, 252
Animal models:
C3H mice, 453
C57BL/6, 453
murine, 147
murine pneumonia, 453
rodent, 328
Animal models/studies:
cats/dogs/cows/horses/pigs, 204
mice/rats, 252
Animal studies, 306
Antibacterial peptide:
pertussis toxin, 273
U-7 3122, 273
Antibodies:
IgA, 328
IgG subclasses, 66
IgG1; IgG2; IgG3; IgG4, 462
immunoglobulin genes, 66
monoclonal, 328
responses, 66
Antigen induction:
antibody production, 1
Antigen presentation, 138, 165
Antigen presenting cells, 375
Antigens:
GroES, 462
peptides, 462
mannosylation, 422
peripheral T cells, 422
subtypes, 1
T-lymphocyte dependent (TD), 1
T-lymphocyte independent (TI), 1
vaccines, 462
APCs:
bovine monocytes, 41
dendritic cells, 41
macrophages, 41
Apotosis, 8
Autoimmunity, 252, 254
human, 223
saliva, 223
Sjogren's syndrome, 223

B cells, 248
B-lymphocyte activators, 1
B lymphocytes:
B-cell line A20, 400
human, 86
naïve splenic B cells, 400
PBMC, 86
Bare lymphocyte syndrome (BLS):
B cells, 53
CIITA, 53
RFX5, 53

C3 fragments, 86
Ca^{2+} signalling, 8
Cancer:
DU145, 291
prostate, 291
Cell structure:
golgi apparatus, 173
microtubules, 173
Cell-mediated immunity:
CD40, 323
Chemokine receptors:
CCR3, 107
CXCR3, 107
CXCR4, 107
Chemokines:
AOP-RANTES, 417
CCR5, 417
chemotaxis, 407
CXCL8, 407
CXCR1, 407
Chemotaxis, 107, 391, 435
Chemotaxis:
chemoattractants, 273
human β defensins (hβD), 273
Chlamdydia:
Chlamdydia trachomatis, 453
mouse pneumonia (MoPn), 453
Class-switch recombination, 212
Collectin:
inflammatory conditions, 91
surfactant protein A, 91
Common variable immunodeficiency:
hyper IgM type 4, 212
non-functional IgG, 212
Complement, 435
Complement activation:
alternative pathway, 86
classical pathway, 86
Contact sensitivity, 118
Co-stimulation:
antigen presenting cells, 19
B7-1, 384
B7-2, 384
CD28, 384
CD40, 19
monoclonal antibodies, 384
T cell, 19
CTL, 254
Cytokine, 298, 357
Cytokines:
IFN-γ, 35, 75, 100, 155
IL-1β, 416
IL-2, 155
IL-4, 35, 75, 100, 155
IL-5, 35
IL-10, 41, 155
IL-12, 41, 173
inflammatory, 223
MIF, 155
TGF-β1, 155, 223
TNF, 41
TNF-α, 416

DEC-205:
bovine orthologue:
WC6 antigen, 262
CD 205, 262
Defensins:
human β defensin (hBD), 444
hBD-1; -2; -3, 444
Dendritic cells, 435
activation, 173
afferent lymph, 262
bovine, 262
human, 173
mannose receptors, 422
proliferative assay, 422
Diabetes, 252
proinsulin, 422
type I, 422
Disease susceptibility/resistance, 318
DNA vaccines, 16, 282
Drug abuse, 357

ELISA:
elastase digestion, 444
tris buffer, 444

Endotheilial cells, 391
Enzymes:
  protein kinase – C (PKC), 195
  terminal deoxynucleotidyl transferase (TdT), 195
Eosinophils:
  granuloma, 107
  inflammation, 107
  peritoneal exudate, 107
Epstein-Barr virus (EBV):
  BZLF-1 promoter, 223
  Zp-luc, 223
Expression plasmid:
  anti-CD3, 27
  DNA vaccines, 27
  fusion genes, 27
  IL-18, 27
Extracellular matrix:
  laminin, 400

Fas, 8
Fc receptors (FcRs), 204

Gene expression:
  cytokines, 343
  enzymes, 343
Genes:
  promoters, 53
  regulation, 53
  SXY module, 53
Genetics, 318
Germinal centre, 400
Glucocorticoids:
  dexamethasone, 291, 430
  immunosuppressants, 430
GM-CSF:
  asthma, 430
  bronchial epithelial cells, 430

Helminth:
  praziquantel, 343
  schistosomes, 343
  Schistosomiasis mansoni, 343
Helper T cells:
  $CD4^+$, 100
  $CD57^+$, 100
  effector cells, 100
  HNK-1 (CD57), 100
  memory cells, 100
Heparinoids:
  C8S, 417
  heparin, 417
  pentosan, 417
HLA, 318

IFN, 186
IFN-γ, 298
IL-18, 16
Immune profiles:
  B-cell responses, 462
  T-cell responses, 462
Immunity, 357
Immunoglobulins, 204
  IgG, 212
  IgM, 212
Immunotherapy:
  antibody, 291
  complement, 291
  MUC 1, 291
Inflammation, 298
Inflammatory mediators, 298
Innate immunity:
  phagocytosis, 472
Insulin, 138
Integrin:
  α6, 400
  differentiation, 400
Intraepithelial lymphocytes (IEL):
  murine, 155
  γδ T-cell clones, 155

Langherhan's cells:
  lymph nodes, 118
  skin, 118
Leprosy:
  leprosy reaction type 1, 472
  leprosy reaction type 2, 472
  Mycobacterium leprae, 472
LPS, 384
Lymphocytes:
  B cells, 230
  follicular DC, 230
  T cells, 230
Lymphoid tissue:
  lymph node, 230

Macrophages, 323
  activation, 416
  $CD68^+$, 472
  chemotaxis, 416
  human, 416
  IFN-γ stimulation, 453
  MRP8 (S100A8), 472
  MRP14 (S100A9), 472
  nitric oxide, 453
Macrophages/monocytes, 282
Matrix metalloproteinases (MMPs), 343
MDMA, 357
Membrane Attack Complex (MAC), 86
MHC Class I:
  HLA-E, -F, -G, 53
MHC Class II:
  $I\text{-}A^b$, 165
  MIF, 155
  transmembrane region, 165
MHC, 376
Mouse models:
  C57B1/6, 323
Mucosal immunity:
  epithelial cells, 75, 91
  HT29 cells, 75
  human vagina, 91
Mycobacteria:
  leprosy, 462
  Mycobacterium avium, 323
  tuberculosis, 462
Mycobacterium, 318

Neuroimmunology, 254
  nerve fibres, 118
  neurotoxin, 118
Neutrophils, 8, 273
apoptosis, 186
human, 186
NF-κB:
  inhibitors, 75
  IκBα-serine, 75
  transcription, 430
  transcription factor, 75
Nitric oxide, 41
NK cells, 298
  $CD3^+CD56^+$, 384
  $CD3^-CD56^+$, 384
  human, 384

Oral tolerance:
  anergy, 19

Parasites:
  Schistosoma japonicum, 107
Passive protection, 328
Pattern recognition receptors:
  bacterial signalling, 173
  TLR2, 173
  TLR4, 173
  toll like receptors, 173
Peripheral antigen expressing (PAE) cells, 138
Polymeric immunoglobulin (PIg):
  PIg receptor, 75
Primates:
  rhesus macaque, 66
Proinsulin, 138
Proliferation:
  TCR, 129

Prostagladin, 298
Protein tyrosine kinases:
  phosphotidylinositol 3, 407
  pyk2, 407
  Src, 407
  tyrosine phosphorylation, 407

Reactive oxygen intermediates (ROI), 41
Rheumatoid arthritis:
  CIA, 35

Self-tolerance/tolerance, 138
Signal transduction:
  inhibitors, 223
  MAPK kinase pathway, 223
Signalling pathway:
  ERK, 41
  human neutrophils, 407
  neutrophil migration, 407
  PICC isoform, 41
Signalling/signal transduction, 368
Somatic hypermutation, 212
Spleen/lymph nodes, 248
Streptococcal inhibitor of complement (SIC):
  extracellular proteins, 444
  group A streptococci (GAS), 444
  streptococcus pyogenes (M1 strain), 444
Stress, 357

T-cell cytokines:
  IFN-γ, 462
T-cell function:
  proliferation, 147
  signalling, 147
  T-cell receptor, 147
T-cell receptors, 308, 375
Tolerance, 375
T-cell response:
  cAMP elevating agents, 35
  Th1/Th2, 35
T cells, 179, 248, 368, 391
  eosinophils, 306
  HUT 78, 430
  human, 430
  jurkat, 430
  Th1, 453
  Th2, 453
T lymphocytes, 375
  T-helper response, 27
  Th1/Th2 cells, 27
T-regulatory cells:
  $CD4^+$ $CD25^+$, 129
Th1, 18
Thymus, 138
Tissue inhibitors of metalloproteinases (TIMPs), 343

TLRs:
  ligands, 41
  TLR2, 41
  TLR4, 41
TNF superfamily:
  immune surveillance, 186
  TRAIL, 186,
  TRAIL receptor, 186
Tolerance, 375:
  antigen, 155
  oral, 155
Toll-like receptors:
  animal models, 179
  mycobacterium, 179
Trafficking:
  endocytic transport, 165
Transcription factor:
  AP-1, 195
  autoimmune disease, 147
  bHLH, 147
  E2A, 147
  gene expression, 147, 195
  nuclear factor, 195
Transgenic/knockout, 252, 254
Transplantation:
  pancreatic islets, 416
TSE:
  prion, 230
  scrapie, 230
  sheep, 230
Tuberculosis, 318
  bacterial, 328
  human, 100
  lung, 328
Type 1 diabetes (T1D, IDDM), 138

Vaccination:
  alum adjuvant, 334
  BALB/c mice, 334
  intradermic, 334
  serum anti-Sap 2 antibodies, 334
Virulence factors:
  Sap 2, 334
  secreted aspartic proteinases (Saps), 334

Yeast:
  Candida albicans, 334
  candidiasis, 334